Patents Assigned to Institute Gustave Roussy
  • Expression of isoform 202 of ERCC1 for predicting response to cancer chemotherapy
    Patent number: 9702875
    Abstract: An in vitro method for detecting the susceptibility of a tumor cell to a chemotherapy is disclosed. The method includes the step of measuring the expression level of the isoform 202 of the ERCC1 protein.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: July 11, 2017
    Assignee: INSTITUTE GUSTAVE-ROUSSY
    Inventors: Ken Olaussen, Jean-Charles Soria, Luc Friboulet
  • EXPRESSION OF ISOFORM 202 OF ERCC1 FOR PREDICTING RESPONSE TO CANCER CHEMOTHERAPY
    Publication number: 20140170659
    Abstract: An in vitro method for detecting the susceptibility of a tumor cell to a chemotherapy is disclosed. The method includes the step of measuring the expression level of the isoform 202 of the ERCC1 protein.
    Type: Application
    Filed: February 21, 2014
    Publication date: June 19, 2014
    Applicant: INSTITUTE GUSTAVE-ROUSSY
    Inventors: Ken Olaussen, Jean-Charles Soria, Luc Friboulet
  • EXPRESSION OF ISOFORM 202 OF ERCC1 FOR PREDICTING RESPONSE TO CANCER CHEMOTHERAPY
    Publication number: 20140120543
    Abstract: An in vitro method for detecting the susceptibility of a tumor cell to a chemotherapy is disclosed. The method includes the step of measuring the expression level of the isoform 202 of the ERCC1 protein.
    Type: Application
    Filed: September 9, 2013
    Publication date: May 1, 2014
    Applicant: INSTITUTE GUSTAVE-ROUSSY
    Inventors: Ken Olaussen, Jean-Charles Soria, Luc Friboulet
  • Sensitization process for antigen-presenting cells and means for implementing the process
    Patent number: 7625573
    Abstract: The object of the invention is a novel sensitization process for antigen-presenting cells, novel means for implementing the process and novel membrane vesicles possessing immunogenic potency. The invention relates in particular to texosomes (vesicles derived from tumor cells) and dexosomes (vesicles derived from dendritic cells loaded or not with antigens), and their use for the vectorization and presentation of antigens in vitro or in vivo as well as in methods or compositions for the treatment of cancers and infectious, parasitic or autoimmune diseases in particular.
    Type: Grant
    Filed: July 2, 2003
    Date of Patent: December 1, 2009
    Assignees: Cetre National de la Recherche Scientifique, Institute Curie, Institute Gustave Roussy
    Inventors: Laurence Zitvogel, Graça Raposo, Armelle Regnault, Sebastian Amigorena